Matthew Wolfgang, PhD

Chapel Hill, North Carolina, United States
Dr. Wolfgang received his PhD in Cellular and Molecular Biology from the University of Michigan in 1999. He completed his postdoctoral studies, as a Cystic Fibrosis Foundation Fellow, at the University of Washington and Harvard Medical School, where he studied bacterial gene regulation in the context of lung infections. Dr. Wolfgang started his faculty career at the University of North Carolina at Chapel Hill in 2003 as a member of the Department of Microbiology and Immunology and the Marsico Lung Institute. For much of his early career, his research focused on signaling networks that coordinate virulence in the opportunistic bacterial pathogen Pseudomonas aeruginosa. Over the past decade, his lab has developed a multidisciplinary, collaborative approach to study respiratory infection from bench to bedside. Early in the SARS-CoV-2 pandemic, Dr. Wolfgang established the Infection Induced Disease (I2D) Therapeutics Initiative at UNC to address the need for personalized treatments for COVID-19. I2D uses a lung-specific multiomics approach to identify the underlying cellular and molecular pathways that drive virus induced respiratory failure. With support from Rapidly Emerging Antiviral Drug Development Initiative (READDI) and in collaboration with SAS, I2D is leveraging electronic health records to develop a personized medicine approach to target SARS-CoV-2 induced disease pathways using repurposed drugs. This disease phenotyping platform has the potential to improve COVID-19 outcomes and to inform therapies for other endemic and potential pandemic viruses.
Speaking In
4:15 PM - 5:15 PM (PDT)
Wednesday, June 15
Developing new therapeutics takes significant time and resources. Even when Federal agencies and…